Valuation: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Market Cap 24.6B 3.63B 3.19B 2.97B 2.72B 5.12B 350B 5.19B 35.23B 13.77B 172B 13.64B 13.34B 595B P/E 2024
10.7x
P/E 2025 16.5x
Enterprise Value 20.34B 3B 2.64B 2.45B 2.25B 4.23B 289B 4.3B 29.14B 11.38B 142B 11.28B 11.03B 492B EV / Sales 2024
2.3x
EV / Sales 2025 5.39x
Free-Float
31.71%
Yield 2024
4.16%
Yield 2025 10.5%
07-14 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026 CI
07-14 Tianjin Pharmaceuticals Warns of Up to 68% Plunge in H1 Profit MT
06-25 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Adjustments to the Composition of the Respective Board Committees CI
05-20 Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender MT
05-15 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Appointment of Zhai Shuping as Independent and Non-Executive Director, Effective May 15, 2026 CI
05-15 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Liew Yoke Pheng Joseph as Independnet and Non-Executive Director, Chairman of the Audit Committee and A Member of the Remuneration Committee CI
04-30 Singapore Shares Surge More Than 1% as DBS Books Record Total Income MT
04-30 Tianjin Pharmaceuticals Da Ren Tang's Attributable Profit Jumps 13% in Q1; Shares Up 5% MT
04-29 Tianjin Pharmaceutical Da Ren Tang posts qtrly revenue of RMB1.52 billion RE
04-29 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025 MT
03-31 Singapore Shares Remain in Red Amid Soaring Energy Costs; Rex International Plunges 20% MT
03-30 Tianjin Pharmaceutical Da Ren Tang to Renew Financial Services Agreement with Tianjin Pharmaceutical Group Finance MT
1 day-2.43%
1 week-5.98%
Current month-1.64%
1 month-3.07%
3 months-9.29%
6 months-20.20%
Current year-19.75%
1 week 36.61
Extreme 36.61
39.39
1 month 34.7
Extreme 34.7
40.36
Current year 34.7
Extreme 34.7
48.2
1 year 34.7
Extreme 34.7
50.97
3 years 23.4
Extreme 23.4
50.97
5 years 17.98
Extreme 17.98
56.26
10 years 11.8
Extreme 11.8
56.26
Manager TitleAgeSince
Director of Finance/CFO 48 2023-07-20
Chief Tech/Sci/R&D Officer 56 2017-10-09
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2024-11-25
Director/Board Member 56 2012-11-30
Director/Board Member 55 2021-12-09
Date Insider Type Main position Quantity % Market Cap.
1/8/20 Buy

Executive/Senior Manager

70,000 0.0124%
1/8/20 Buy

Executive/Senior Manager

70,000 0.0124%
1/8/20 Buy

Director

70,000 0.0124%
Change 5-day change 1-year change 3-year change Capi.($)
-2.43%-5.98%+0.91%-10.00% 3.71B
-1.35%-2.13%-9.78%-4.66% 13.62B
-2.94%-6.94%-30.83%-51.75% 5.23B
-0.78%-1.01%-0.22%-1.78% 4.83B
-3.19%-5.64%+4.53%-32.23% 4.18B
-1.33%+1.56%-3.41%-3.05% 3.68B
-1.19%-1.07%-2.60%+11.54% 3.52B
-2.28%-4.51%-13.60%-23.22% 2.46B
-3.10%-4.95%-6.29%+44.91% 1.88B
-2.87%-8.97%-19.61%-14.09% 1.72B
Average -2.15%-3.36%-8.09%-8.43% 4.48B
Weighted average by Cap. -1.90%-2.96%-8.34%-10.75%

Financials

2024 2025
Net sales 7.31B 1.08B 948M 881M 809M 1.52B 104B 1.54B 10.47B 4.09B 51.09B 4.05B 3.96B 177B 4.92B 726M 638M 593M 544M 1.02B 69.94B 1.04B 7.04B 2.75B 34.38B 2.73B 2.67B 119B
Net income 2.23B 329M 289M 269M 247M 464M 31.71B 471M 3.19B 1.25B 15.59B 1.24B 1.21B 53.9B 2.13B 315M 276M 257M 236M 443M 30.31B 450M 3.05B 1.19B 14.9B 1.18B 1.16B 51.52B
Net Debt -3.91B -577M -507M -471M -432M -812M -55.55B -825M -5.6B -2.19B -27.31B -2.17B -2.12B -94.43B -4.26B -629M -552M -514M -471M -885M -60.54B -899M -6.1B -2.38B -29.76B -2.36B -2.31B -103B
Logo Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a China-based company principally engaged in the research, development, manufacturing and retail of Chinese herbal medicines, Chinese patent medicines, chemical raw materials and preparations, and nutritional health products. The Company operates its businesses through three segments. The Chinese Patent Medicine segment is mainly engaged in the research, development, manufacturing and sales of Chinese medicines, including Su Xiao Jiu Xin Pill, Jing Wan Hong Ruan Gao, An Gong Niu Huang Pill, Qing Gong Shou Tao Pill and other products. The Western Medicine segment is mainly engaged in the research, development, manufacturing and sales of Western medicines. The Others segment mainly includes economic information consulting services, house leasing and other businesses. The Company mainly operates its businesses in the domestic and overseas markets.
Employees
3,890
Date Price Change Volume
26-07-23 CN¥36.61 -2.43% 3,373,534
26-07-23 CN¥37.52 -0.45% 3,043,700
26-07-22 CN¥37.69 -1.10% 4,387,426
26-07-21 CN¥38.11 -1.93% 5,671,663
26-07-20 CN¥38.86 +2.51% 6,071,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 600329 Stock